Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2014

View Archived Issues

Discovery of a novel target in Plasmodium species leading to antimalarial drug development

HD Biosciences and Marshall University form cancer drug discovery agreement

Researchers present promising preclinical data for HM-12525A

Ipsen, Galderma/Nestle expand aesthetic dermatology businesses

Dignity Sciences reports data from phase II trial of DS-107E in atopic dermatitis

Ventana and Merck KGaA collaborate on companion diagnostic test

Plexxikon discloses new c-Kit inhibitors for cancer

Researchers at ChemoCentryx patent new CCR1 receptor antagonists

U.S. team discloses new 5-HT2C receptor agonists

Researchers report in vivo data for ZP-GA-1

Alios BioPharma divulges new NS5B inhibitors for HCV infection

Pfizer patents new EZH2 inhibitors for cancer

BioChaperone Lispro demonstrates a faster onset of action than naive insulin lispro

Bristol-Myers Squibb reports novel Abeta inhibitors

Hanmi presents promising results for HM-71224

ProStrakan to acquire Archimedes Pharma

Topline data reported from coBRIM study of cobimetinib in combination with vemurafenib

Brexpiprazole NDA submitted for schizophrenia and major depressive disorder

European orphan drug designations awarded to isavuconazole

Celgene set to study CC-220 in pilot phase II trial for SLE

Sialix changes name

Pfizer studies PF-06743649 in new phase I program for gout

New clinical data on remogliflozin etabonate presented

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...